Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice

Journal of Hypertension

Volumn 23, Issue 5, 2005, Pages 945-954

  Alexiou, Theodora ^a   Boon, Wee Ming ^a   Denton, Derek A ^a   Di Nicolantonio, Robert ^a   Walker, Lesley L ^a   McKinley, Michael J ^a   Campbell, Duncan J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Angiotensin I; Angiotensin II; Angiotensin converting enzyme; Angiotensinogen; Bradykinin; Knockout; Mice

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSINOGEN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE;

ADRENAL GLAND; ANGIOTENSIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD; BRAIN; CONTROLLED STUDY; DNA POLYMORPHISM; GENE EXPRESSION; GENE IDENTIFICATION; HEART; KIDNEY; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 18344367831     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000166834.32817.41     Document Type: Article

References (49)

1. Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1979; 1:287-291.
2. Fasola AF, Martz BL, Helmer OM. Plasma renin activity during supine exercise in offspring of hypertensive parents. J Appl Physiol 1968; 25:410-415.
3. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2003; 23:1269-1275.
4. Kobashi G, Shido K, Hata A, Yamada H, Kato EH, Kanamori M, et al. Multivariate analysis of genetic and acquired factors; T235 variant of the angiotensinogen gene is a potent independent risk factor for preeclampsia. Semin Thromb Hemost 2001; 27:143-147.
5. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
6. Danser AHJ, Schalekamp MADH, Bax WA, Van den Brink AM, Saxena PR, Riegger GAJ, Schunkert H. Angiotensin-converting enzyme in the human heart - effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387-1388.
7. Mizuiri S, Hemmi H, Kumanomidou H, Iwamoto M, Miyagi M, Sakai K, et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int 2001; 60:1124-1130.
8. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997; 15:1579-1592.
9. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, et al., for the International Studies of lnfarct Survival (ISIS) Collaborators. Large-scale test of hypothesised associations between the angiotensin- converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet 2000; 355:434-442.
10. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
11. Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X. Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel. Hypertension 1999; 33:1324-1331.
12. Soubrier F, Nadaud S, Williams TA. Angiotensin I converting enzyme gene: regulation, polymorphism and implications in cardiovascular diseases. Eur Heart J 1994; 15(suppl D):24-29.
13. Smithies O, Kim H-S. Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci USA 1994; 91:3612-3615.
14. Kim H-S, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92:2735-2739.
15. Krege JH, John SWM, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995; 375:146-148.
16. Kim HS, Maeda N, Oh GT, Fernandez LG, Gomez RA, Smithies O. Homeostasis in mice with genetically decreased angiotensinogen is primarily by an increased number of renin-producing cells. J Biol Chem 1999; 274:14210-14217.
17. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991; 18:763-773.
18. Johansen KB, Marstein S, Aas P. Automated method for the determination of angiotensin-converting enzyme in serum. Scand J Clin Lab Invest 1987; 47:411-414.
19. Campbell DJ, Lawrence AC, Kladis A, Duncan A-M. Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues. In: Smith AI., editor. Methods in neurosciences, volume 23: peptidases and neuropeptide processing. Orlando, FL: Academic Press; 1995, pp. 328-343.
20. Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P, Bernstein KE. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 2004; 43:854-859.
21. Kim HS, Lee G, John SW, Maeda N, Smithies O. Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc Natl Acad Sci USA 2002; 99:4602-4607.
22. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449.
23. Klett C, Hellmann W, Suzuki F, Nakanishi S, Ohkubo H, Ganten D, Hackenthal E. Induction of angiotensinogen mRNA in hepatocytes by angiotensin II and glucocorticoids. Clin Exp Hypertens [A] 1988; 10:1009-1022.
24. Tamura K, Umemura S, Sumida Y, Nyui N, Kobayashi S, Ishigami T, et al. Effect of genetic deficiency of angiotensinogen on the renin-angiotensin system. Hypertension 1998; 32:223-227.
25. Campbell DJ. The renin-angiotensin and the kallikrein-kinin systems. Int J Biochem Cell Biol 2003; 35:784-791.
26. Tian BH, Meng QC, Chen YF, Krege JH, Smithies O, Oparil S. Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function. Hypertension 1997; 30:128-133.
27. Krege JH, Kim HS, Moyer JS, Jennette JC, Peng L, Miller SK, Smithies O. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 1997; 29:150-157.
28. Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001; 142:5220-5225.
29. 1B receptors for angiotensin II. Proc Natl Acad Sci USA 1998; 95:15496-15501.
30. Krege JH, Kim HS, Moyer JS, Jennette JC, Peng L, Hiller SK, Smithies O. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 1997; 29:150-157.
31. Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98:13330-13334.
32. Esther CR Jr, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996; 74:953-965.
33. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994; 269:31334-31337.
34. Azizi M, Junot C, Ezan E, Hallouin MC, Guyene T, Menard J. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production. J Mol Med 2002; 80:492-498.
35. Celerier J, Cruz A, Lamande N, Gasc JM, Corvol P. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 2002; 39:224-228.
36. Campbell DJ, Kladis A, Briscoe TA, Zhuo J. Type 2 bradykinin-receptor antagonism does not modify kinin or angiotensin peptide levels. Hypertension 1999; 33:1233-1236.
37. Danser AH, Derkx FH, Hense HW, Jeunemaitre X, Riegger GA, Schunkert H. Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 1998; 16:1879-1883.
38. Harrap SB, Davidson HR, Connor JM, Soubrier F, Corvol P, Fraser R, et al. The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 1993; 21:455-460.
39. Lachurié M-L, Azizi M, Guyene T-T, Alhenc-Gelas F, Ménard J. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995; 91:2933-2942.
40. Ueda S, Elliott HL, Morton JJ, Connell JMC. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995; 25:1266-1269.
41. Chadwick IG, O'Toole L, Morice AH, Yeo WW, Jackson PR, Ramsay LE. Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes. J Cardiovasc Pharmacol 1997; 29:485-489.
42. Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott HL. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98:2148-2153.
43. Danser AH, Deinum J, Osterop AP, Admiraal PJ, Schalekamp MA. Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion/deletion polymorphism. J Hypertens 1999; 17:1867-1872.
44. Rossi GP, Narkiewicz K, Cesari M, Winnicki M, Bigda J, Chrostowska M, et al. Genetic determinants of plasma ACE and renin activity in young normotensive twins. J Hypertens 1999; 17:647-655.
45. van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, Chang PC. The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. J Cardiovasc Pharmacol 2000; 35:484-490.
46. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Bur Heart J 1996; 17:787-794.
47. Steeds RP, Toole LO, Channer KS, Morice AH. Human vascular reactivity and polymorphisms of the angiotensin-converting enzyme and the angiotensin type 1 receptor genes. J Vasc Res 1999; 36:445-455; discussion 535-448.
48. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000; 102:829-832.
49. Skinner SL, Lumbers ER, Symonds EM. Alteration by oral contraceptives of normal menstrual changes in plasma renin activity, concentration and substrate. Clin Sci 1969; 36:67-76.